A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

clinical trial

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00385827

P6099clinical trial phasephase II clinical trialQ42824440
P17countrySpainQ29
United States of AmericaQ30
BelgiumQ31
FranceQ142
AustriaQ40
United KingdomQ145
GermanyQ183
P582end time2008-11-01
P921main subjectmetastatic prostate carcinomaQ55779807
P2899minimum age18
P1132number of participants106
P4844research interventionprednisoneQ424972
P580start time2006-11-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Search more.